Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome

ting pain as measured by the Patient Experience Diary (PED), the overall impression of patient well being as measured by the Patient Global Impression of Change (PGIC) and an analysis of physical function as measured by the SF-36 Physical Component Summary for patients receiving either dose of milnacipran compared to placebo. The difference between active doses and placebo was assessed by a responder analysis with a responder defined as a subject meeting the criteria for the treatment of pain associated with fibromyalgia and in addition showing improvement in physical function as assessed by the SF-36 Physical Component Summary.

Treatment of Pain Associated with Fibromyalgia

This endpoint showed statistically significant improvement for milnacipran compared to placebo for patients receiving 200 mg per day of milnacipran (p=0.004) and for patients receiving 100 mg per day of milnacipran (p=0.025).

These results were analyzed using the Baseline Observation Carried Forward (BOCF) analysis, as agreed to with the U.S. Food and Drug Administration (FDA).

Treatment of Fibromyalgia Syndrome

This endpoint also showed statistically significant improvement for milnacipran compared to placebo for both the 200mg per day dose (p=0.015) and 100mg per day dose (p=0.011) using the Baseline Observation Carried Forward (BOCF) analysis. Results for both endpoints listed above were also statistically significant when analyzed using a Last Observation Carried Forward (LOCF) method.

Component Assessments

In addition, when analyzed according to the pre-specified analysis plan both the pain and the PGIC components of the composite endpoint individually achieved statistical significance in favor of milnacipran at both doses and the SF-36 Physical Component Summary met statistical significance at one dose.

Tolerability

Milnacipran was generally well tolerated, with the majority of patient withdrawals occurring early in the trial.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  In part ... to leverage a hospital pharmacy as a strategic asset, ... national practice leader for Cardinal Health,s Innovation Delivery Solutions ... care can benefit both hospitals and patients. ... only one part of their job in a value-based ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
... 14 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH), provides ... in the company,s name, ticker symbol and CUSIP number. ... FINRA all documentation requested in connection with the name change, ... number for the company,s common shares. FINRA is working ...
Cached Medicine Technology:AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change 2
(Date:8/30/2014)... 2014 Continuing to meet the skin ... with the addition of a new doctor and office ... provided leading-edge skin care in Grand Rapids since 1980 ... “As a doctor, my passion is making sure my ... Forefront Dermatology, I’m better able to focus on my ...
(Date:8/30/2014)... 2014 Hastings and Hastings, a qualified ... throughout Arizona is pleased to report having saved a ... example among many cases where Hastings and Hastings has ... retain a greater portion of their settlement or recovery. ... a positive solution for Arizona car accident victims is ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Lab ... The report then explores global and China’s top ... capacity, production value, and market share etc. , ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Bringing ... Profit By Search announces the Labor Day discount ... clients will surely get the complete services related to ... SEO professionals, Content Writers, and others do have a ... perfection that reflects in their work and since the ...
(Date:8/30/2014)... lead extraction (TLE) is clinically successful in more than ... Lead Extraction ConTRolled (ELECTRa) registry presented for the first ... Grazia Bongiorni, chair of the registry,s executive committee. , ... devices (CIED) implant procedures has grown in recent years. ... increased and leads are often the cause. TLE is ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3
... better with heart failure, says a new study. // ... analysed the records of over 100,000 patients hospitalised because their ... Scientist. , ,They found that the fatter the person, ... hospital stay. The researchers reported their findings in the latest ...
... Since August 2006, Hong Kong authorities have been warning residents ... infections on fish eggs and considered dangerous for human health. ... the mainland have tested positive for malachite green. ... is the biggest mainland fish marketer, shipping a total of ...
... 1,000 children around the world were infected by HIV in each ... // ,In total, around 410,000 to 660,000 children under ... U.N. agency said. ,The report added that most of ... HIV-positive mothers and about half of the children infected last year ...
... the World Health Organization's tuberculosis drug-resistant unit, this week ... Washington, D.C., to discuss funding to combat extensively drug-resistant ... first- and second-line drugs -- VOA News reports. ... combat XDR-TB in Africa is roughly $300 million over ...
... increasingly important method for detecting malaria. Health specialists recommend ... other strategies for controlling the disease // , including ... indoor spraying against malaria-carrying mosquitoes and testing and treatment ... tests are ideal for rural areas are accurate, easy ...
... Researchers find that aspirin saves the life of cancer ... believe that majority of these patients will die// if ... turns common medical assumptions upside down and will likely ... thin blood and cancer patients experience low platelet counts ...
Cached Medicine News:Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3Health News:Aspirin Saves Life Even in Cancer Patients 2Health News:Aspirin Saves Life Even in Cancer Patients 3
... while minimizing the pain of ... safety-engineered BD Microtainer Genie Lancet. ... offers a full range of ... blood collection and protects the ...
The DiaSTAT™ is an automated liquid chromatography system designed for the rapid and automated analysis of hemoglobin A1C. Ideal for low and ,medium volume testing environments....
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia...
Inquire...
Medicine Products: